Paper36960932
Recent Developments in Nanoparticle-Based Photo-Immunotherapy for Cancer Treatment.
Guo Z and 3 others. Small Methods, 2023. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Recent Developments in Nanoparticle-Based Photo-Immunotherapy for Cancer Treatment. Papers, record 36960932. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36960932
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Nanoparticles | Major topic |
| Humans | |
| Phototherapy | |
| Immunotherapy | |
| Drug Delivery Systems |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R21 AI159492 | NIAID NIH HHS | United States | R21AI159492 | PubMed and NIH |
| R21AI159492 | NIH HHS | United States | R21AI159492 | PubMed and NIH |
Source NIH RePORTER
References225
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35735086 | Engineered Red Blood Cell Membrane-Coating Salidroside/Indocyanine Green Nanovesicles for High-Efficiency Hypoxic Targeting Phototherapy of Triple-Negative Breast Cancer. | Adv Healthc Mater | 2022 | https://conductscience.org/library/papers/35735086 | PubMed |
| 2 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 3 | 32271563 | Reprogramming Tumor Microenvironment with Photothermal Therapy. | Bioconjug Chem | 2020 | https://conductscience.org/library/papers/32271563 | PubMed |
| 4 | 34504391 | Perfluorocarbon nanomaterials for photodynamic therapy. | Curr Opin Colloid Interface Sci | 2021 | https://conductscience.org/library/papers/34504391 | PubMed |
| 5 | 34611678 | Near infrared photothermal conversion materials: mechanism, preparation, and photothermal cancer therapy applications. | J Mater Chem B | 2021 | https://conductscience.org/library/papers/34611678 | PubMed |
| 6 | 36242941 | Red blood cell membrane nanoparticles for tumor phototherapy. | Colloids Surf B Biointerfaces | 2022 | https://conductscience.org/library/papers/36242941 | PubMed |
| 7 | 29113417 | Porphyrin photosensitizers in photodynamic therapy and its applications. | Oncotarget | 2017 | https://conductscience.org/library/papers/29113417 | PubMed |
| 8 | 30444351 | Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. | ACS Nano | 2018 | https://conductscience.org/library/papers/30444351 | PubMed |
| 9 | 25615236 | Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. | Nano Lett | 2015 | https://conductscience.org/library/papers/25615236 | PubMed |
| 10 | 33290263 | Enhancer-bound Nrf2 licenses HIF-1α transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells. | Aging (Albany NY) | 2020 | https://conductscience.org/library/papers/33290263 | PubMed |
| 11 | 33824489 | Emerging concepts in the science of vaccine adjuvants. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33824489 | PubMed |
| 12 | 27532320 | Carbon-Dot-Decorated Carbon Nitride Nanoparticles for Enhanced Photodynamic Therapy against Hypoxic Tumor via Water Splitting. | ACS Nano | 2016 | https://conductscience.org/library/papers/27532320 | PubMed |
| 13 | 32979727 | Alleviating tumor hypoxia with perfluorocarbon-based oxygen carriers. | Curr Opin Pharmacol | 2020 | https://conductscience.org/library/papers/32979727 | PubMed |
| 14 | 31202726 | Light triggered oxygen-affording engines for repeated hypoxia-resistant photodynamic therapy. | J Control Release | 2019 | https://conductscience.org/library/papers/31202726 | PubMed |
| 15 | 36442438 | Repeated photodynamic therapy mediates the abscopal effect through multiple innate and adaptive immune responses with and without immune checkpoint therapy. | Biomaterials | 2023 | https://conductscience.org/library/papers/36442438 | PubMed |
| 16 | 31847487 | Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. | Cells | 2019 | https://conductscience.org/library/papers/31847487 | PubMed |
| 17 | 25049431 | Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. | J Immunol | 2014 | https://conductscience.org/library/papers/25049431 | PubMed |
| 18 | 35967738 | Stem cell membrane-camouflaged targeted delivery system in tumor. | Mater Today Bio | 2022 | https://conductscience.org/library/papers/35967738 | PubMed |
| 19 | 17101732 | Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. | J Exp Med | 2006 | https://conductscience.org/library/papers/17101732 | PubMed |
| 20 | 25082815 | CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. | Cancer Res | 2014 | https://conductscience.org/library/papers/25082815 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42233111 | Assessment of Anticancer Effect of Rhodium Nanoparticle-based Photodynamic Therapy via Protein-Protein Interaction Network Analysis. | J Lasers Med Sci | 2026 | https://conductscience.org/library/papers/42233111 | PubMed |
| 42077816 | Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity. | Nanoscale Adv | 2026 | https://conductscience.org/library/papers/42077816 | PubMed |
| 41948173 | Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41948173 | PubMed |
| 41939214 | Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41939214 | PubMed |
| 41646191 | A mini-review: photodynamic therapy-induced immune activation. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41646191 | PubMed |
| 41366426 | Macrophage membrane-coated nanoparticles in inflammatory diseases: from bioinspired design to translational potential. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/41366426 | PubMed |
| 41334375 | Barrier-disrupting microneedle technology: Overcoming physical, physiological, and pathological skin defenses to enhance therapeutic efficacy. | Bioact Mater | 2026 | https://conductscience.org/library/papers/41334375 | PubMed |
| 40878947 | New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review). | Int J Mol Med | 2025 | https://conductscience.org/library/papers/40878947 | PubMed |
| 40788347 | Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer. | Drug Deliv Transl Res | 2025 | https://conductscience.org/library/papers/40788347 | PubMed |
| 40470111 | Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40470111 | PubMed |
| 40264819 | Illuminating Hope for Tumors: The Progress of Light-Activated Nanomaterials in Skin Cancer. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40264819 | PubMed |
| 40058873 | Diverse nanoparticles deliver mRNA to enhance tumor immunotherapy. | BMB Rep | 2025 | https://conductscience.org/library/papers/40058873 | PubMed |
| 40027868 | Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40027868 | PubMed |
| 39655738 | Immunogenic cell death: A new strategy to enhancing cancer immunotherapy. | Hum Vaccin Immunother | 2024 | https://conductscience.org/library/papers/39655738 | PubMed |
| 39128942 | Current advance of nanotechnology in diagnosis and treatment for malignant tumors. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39128942 | PubMed |
| 39078330 | Magnetic Cell Targeting for Cardiovascular Tissue Engineering. | Tissue Eng Part B Rev | 2025 | https://conductscience.org/library/papers/39078330 | PubMed |
| 38764446 | A genetically engineered neuronal membrane-based nanotoxoid elicits protective immunity against neurotoxins. | Bioact Mater | 2024 | https://conductscience.org/library/papers/38764446 | PubMed |
| 38407670 | Theranostics: a multifaceted approach utilizing nano-biomaterials. | Discov Nano | 2024 | https://conductscience.org/library/papers/38407670 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| ANXA1 | 301 | PubTator's text mining | https://conductscience.org/library/genes/301 | NCBI Gene |
| CALR | 811 | PubTator's text mining | https://conductscience.org/library/genes/811 | NCBI Gene |
| CARTPT | 9607 | PubTator's text mining | https://conductscience.org/library/genes/9607 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| GPC3 | 2719 | PubTator's text mining | https://conductscience.org/library/genes/2719 | NCBI Gene |
| HAS1 | 3036 | PubTator's text mining | https://conductscience.org/library/genes/3036 | NCBI Gene |
| PLK1 | 5347 | PubTator's text mining | https://conductscience.org/library/genes/5347 | NCBI Gene |
| TF | 7018 | PubTator's text mining | https://conductscience.org/library/genes/7018 | NCBI Gene |
| TFRC | 7037 | PubTator's text mining | https://conductscience.org/library/genes/7037 | NCBI Gene |
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36960932
GET https://conductscience.org/api/papers/v1/36960932/references?page=2